Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Dec 02, 2020 11:41am
132 Views
Post# 32018091

RE:RE:RE:Cydy in Nash!

RE:RE:RE:Cydy in Nash!Yes exactly, I listened to their CEO on drbeen(YouTube) he is so passionated about their company and it's prospects it was almost hard not to believe him! Paul seems to have the same set of skills so bring it on....
 
qwerty22 wrote:

It's targeted against CCR5, the same as another drug Mariviroc. Mariviroc is actually also being tested in all the same indications as cydy's drug. Hiv entry, cancer, Covid and Nash. The company are certainly gung-ho about chasing these different indications but I don't think completely blindly. All you can really say is they seem to be the opposite end of the conservatism scale to THTX. The Oslo site end on many scales probably, go to their website and the first thing you see is a wall of promotion.

 

Bucknelly21 wrote: Wow... that drug is the all-in-one... lol 

 

 



<< Previous
Bullboard Posts
Next >>